

Gadopiclenol (marketed under the name Vueway® by Bracco) receives the JFR* 2024 Innovation Award - Jury's Favorite category



Milano, 4th October 2024: Bracco Imaging, a global specialist in contrast media and solutions for medical imaging, is delighted to announce that Gadopiclenol (marketed as Vueway® by Bracco) has been honored with the JFR* 2024 Innovation Award in the Jury's Favorite category.

This contrast agent represents a major advance in the field of magnetic resonance imaging (MRI).

Gadopiclenol is distinguished by its high relaxivity and high stability, providing images of equivalent quality to the macrocyclic gadolinium contrast agents currently available on the market, while using lower dose of gadolinium than those approved for general-purpose gadolinium-based contrast agents (indeed, a dose of 0.05 mmol/kg is sufficient, compared to 0.1 mmol/kg for most of the other macrocyclic gadolinium contrast agents).

Indicated for adults and children 2 years of age and older, Gadopiclenol improves the detection and visualization of conditions associated with disruption of the blood-brain barrier (BBB) and/or abnormal vascularization in:

- the brain, spine, and other associated tissues of the central nervous system (CNS);
- the liver, kidney, pancreas, breast, lung, prostate and musculoskeletal system ([Vueway, gadopiclenol \(europa.eu\)](https://www.bracco.eu/vueway-gadopiclenol)).

Thanks to its efficacy, safety and the use of lower-doses, Gadopiclenol exemplifies Bracco's commitment to medical innovation and environmental responsibility providing a cutting-edge solution for medical imaging while reducing the ecological footprint of MRI scans.

The Marketing Authorization (MA) for (Gadopiclenol) was granted to Bracco and Guerbet by the European Commission on December 7, 2023, following approval by the FDA in September 2022. Gadopiclenol is marketed independently by Bracco and Guerbet.

The award ceremony will take place on October 6 at 12:15 p.m., during the Francophone Days of Radiology at the Palais des Congrès in Paris.

Fulvio Renoldi Bracco, CEO, and all Bracco Imaging employees thank the JFR 2024 jury for this prestigious recognition and reaffirm their commitment to pursuing innovation in medical imaging for the benefit of patients and healthcare professionals.

*JFR: Journées Francophones de la Radiologie (Francophone Days of Radiology)

Contacts:

Bracco

Carolina Bargoni, Communication Director: +39 347 5397738 / carolina.bargoni@bracco.com



COMMUNIQUE DE PRESSE

About Bracco Imaging

Bracco Imaging S.p.A. ("Bracco Imaging"), part of the Bracco Group, is an innovative world leader delivering end-to-end products and solutions through its comprehensive portfolio across diagnostic imaging modalities. Headquartered in Milan, Italy, Bracco Imaging's purpose is to improve people's lives by shaping the future of prevention and precision diagnostic imaging. The Bracco Imaging portfolio includes products and solutions for all key diagnostic imaging modalities: X-ray imaging, magnetic resonance imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine through radioactive tracers and novel PET imaging agents. Bracco Imaging has 3,800 employees and operates in more than 100 markets globally. Bracco Imaging has a well-skilled and innovative Research and Development (R&D) organization with an efficient process-oriented approach and track record in the diagnostic imaging industry. Discover Bracco at www.bracco.com

About Gadopiclenol

Gadopiclenol, initially invented by Guerbet, with the subsequent contribution of intellectual property held by Bracco, is a new gadolinium-based macrocyclic contrast agent (GBCA) with high relaxivity. The efficacy and safety of Gadopiclenol have been evaluated in MRI of the central nervous system, head and neck, chest, abdomen, pelvis and musculoskeletal system. The Summary of Product Characteristics can be found at ([Vueway, gadopiclenol \(europa.eu\)](http://Vueway.gadopiclenol.europa.eu)).

Details of phase III clinical trials are available in the database of www.ClinicalTrials.gov:

- Efficacy and Safety of Gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI) Full Text View - ClinicalTrials.gov
- Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging (MRI) Full Text View -gov

About the Guerbet / Bracco Imaging collaboration

In December 2021, Bracco Imaging and Guerbet concluded a global collaboration for the production of Gadopiclenol and research and development activities. Gadopiclenol will be marketed independently under separate brands. Guerbet and Bracco Imaging each own valuable intellectual property for Gadopiclenol. Furthermore, after an agreed transitional period during which Guerbet will produce Gadopiclenol for both Guerbet and Bracco Imaging, both companies will produce the active ingredient and the finished product Gadopiclenol. This strategic collaboration is expected to accelerate access to Gadopiclenol, innovate and improve care for patients and healthcare professionals.

Contacts:

Bracco

Carolina Bargoni, Communication Director: +39 347 5397738 / carolina.bargoni@bracco.com